Analyst consensus rating
Cardiff Oncology Analyst Rating: none
Direct answer
Cardiff Oncology's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.81.
Forecast evidence checked October 1, 2026.
Get free Cardiff Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.21
- Average price target
- $5.81
- High price target
- $12.00
- Low price target
- $1.20
- Low target gap
- -0.8%
- Target upside
- +380.5%
- High target gap
- +891.7%
- Target range width
- 892.6%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- October 1, 2026
- Valid through
- October 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cardiff Oncology?
Cardiff Oncology has a verified none consensus. The same dataset has an average price target of $5.81.
How far are Cardiff Oncology's low and high targets from the recorded price?
The low target implies -0.8%, while the high target implies +891.7%.
How many analysts are included in Cardiff Oncology's consensus?
The verified consensus includes 7 analysts.
How is Cardiff Oncology's target upside or downside calculated?
The average target of $5.81 is divided by the recorded price of $1.21, then one is subtracted to produce +380.5%. This does not guarantee a future return.
When was Cardiff Oncology's analyst forecast verified?
The data was verified on 2026-10-01. The dataset is valid through 2026-10-08.